Enhancing cancer immunotherapy using a specific lipid compound
Tetraacylated lipid A enhancement of checkpoint blocking cancer immunotherapy
This study is looking at how a natural compound from our gut might help boost the effectiveness of cancer treatments for patients who haven't had success with current therapies, by working alongside a type of treatment that helps the immune system fight cancer.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard Medical School NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10994161 on NIH RePORTER |
What this research studies
This research investigates how a specific compound derived from the gut microbiome, known as tetra-acylated lipid A, can improve the effectiveness of cancer immunotherapy, particularly for patients who do not respond to existing treatments. The study will explore the interaction between this compound and immune checkpoint inhibitors, which are designed to activate the immune system against cancer. By using animal models, the researchers aim to determine if this compound can enhance the response to anti-PD-L1 therapy, potentially leading to better outcomes for patients with certain types of cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients, particularly those with adenocarcinoma, who have not responded to anti-PD-L1 therapy.
Not a fit: Patients who are not diagnosed with cancer or those who have already responded positively to existing immunotherapy treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that significantly improves the effectiveness of cancer immunotherapy for patients who currently do not respond to existing therapies.
How similar studies have performed: Previous research has shown promising results in enhancing cancer immunotherapy through microbiome interactions, suggesting that this approach could be a viable and innovative strategy.
Where this research is happening
Boston, United States
- Harvard Medical School — Boston, United States (Active)
Researchers
- Principal investigator: Kasper, Dennis L. — Harvard Medical School
- Study coordinator: Kasper, Dennis L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.